文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

临床试验中的新型治疗药物:癌症治疗的新兴方法。

Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy.

作者信息

Joshi Deepak Chandra, Sharma Anurag, Prasad Sonima, Singh Karishma, Kumar Mayank, Sherawat Kajal, Tuli Hardeep Singh, Gupta Madhu

机构信息

Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, Bandar Sindri, Dist., Ajmer, Rajasthan, India.

Invertis Institute of Pharmacy, Invertis University Bareilly Uttar Pradesh, Bareilly, India.

出版信息

Discov Oncol. 2024 Aug 11;15(1):342. doi: 10.1007/s12672-024-01195-7.


DOI:10.1007/s12672-024-01195-7
PMID:39127974
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11317456/
Abstract

Novel therapeutic agents in clinical trials offer a paradigm shift in the approach to battling this prevalent and destructive disease, and the area of cancer therapy is on the precipice of a trans formative revolution. Despite the importance of tried-and-true cancer treatments like surgery, radiation, and chemotherapy, the disease continues to evolve and adapt, making new, more potent methods necessary. The field of cancer therapy is currently witnessing the emergence of a wide range of innovative approaches. Immunotherapy, including checkpoint inhibitors, CAR-T cell treatment, and cancer vaccines, utilizes the host's immune system to selectively target and eradicate malignant cells while minimizing harm to normal tissue. The development of targeted medicines like kinase inhibitors and monoclonal antibodies has allowed for more targeted and less harmful approaches to treating cancer. With the help of genomics and molecular profiling, "precision medicine" customizes therapies to each patient's unique genetic makeup to maximize therapeutic efficacy while minimizing unwanted side effects. Epigenetic therapies, metabolic interventions, radio-pharmaceuticals, and an increasing emphasis on combination therapy with synergistic effects further broaden the therapeutic landscape. Multiple-stage clinical trials are essential for determining the safety and efficacy of these novel drugs, allowing patients to gain access to novel treatments while also furthering scientific understanding. The future of cancer therapy is rife with promise, as the integration of artificial intelligence and big data has the potential to revolutionize early detection and prevention. Collaboration among researchers, and healthcare providers, and the active involvement of patients remain the bedrock of the ongoing battle against cancer. In conclusion, the dynamic and evolving landscape of cancer therapy provides hope for improved treatment outcomes, emphasizing a patient-centered, data-driven, and ethically grounded approach as we collectively strive towards a cancer-free world.

摘要

临床试验中的新型治疗药物为对抗这种普遍且具有破坏性的疾病提供了一种范式转变,癌症治疗领域正处于一场变革性革命的边缘。尽管手术、放疗和化疗等经过验证的癌症治疗方法很重要,但这种疾病仍在不断演变和适应,因此需要新的、更有效的方法。目前,癌症治疗领域正在见证多种创新方法的出现。免疫疗法,包括检查点抑制剂、嵌合抗原受体T细胞(CAR-T)治疗和癌症疫苗,利用宿主的免疫系统选择性地靶向并根除恶性细胞,同时将对正常组织的损害降至最低。激酶抑制剂和单克隆抗体等靶向药物的开发,使得治疗癌症的方法更具针对性且危害更小。借助基因组学和分子图谱,“精准医学”根据每位患者独特的基因构成定制治疗方案,以最大限度地提高治疗效果,同时将不良副作用降至最低。表观遗传疗法、代谢干预、放射性药物,以及对具有协同效应的联合疗法的日益重视,进一步拓宽了治疗前景。多阶段临床试验对于确定这些新药的安全性和有效性至关重要,既能让患者获得新的治疗方法,又能增进科学认识。癌症治疗的未来充满希望,因为人工智能和大数据的整合有可能彻底改变早期检测和预防。研究人员、医疗保健提供者之间的合作以及患者的积极参与仍然是当前抗癌斗争的基石。总之,癌症治疗动态且不断演变的格局为改善治疗结果带来了希望,强调在我们共同努力迈向无癌世界的过程中,要采取以患者为中心、数据驱动且符合伦理道德的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fff/11317456/e974a547d95d/12672_2024_1195_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fff/11317456/6558f28be2f6/12672_2024_1195_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fff/11317456/e974a547d95d/12672_2024_1195_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fff/11317456/6558f28be2f6/12672_2024_1195_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fff/11317456/e974a547d95d/12672_2024_1195_Fig2_HTML.jpg

相似文献

[1]
Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy.

Discov Oncol. 2024-8-11

[2]
Systemic treatments for metastatic cutaneous melanoma.

Cochrane Database Syst Rev. 2018-2-6

[3]
The future of Cochrane Neonatal.

Early Hum Dev. 2020-11

[4]
From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?

Curr Oncol Rep. 2018-2-7

[5]
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

J Transl Med. 2016-11-15

[6]
Overview of resistance to systemic therapy in patients with breast cancer.

Adv Exp Med Biol. 2007

[7]
Update on Immunotherapy Cardiotoxicity: Checkpoint Inhibitors, CAR T, and Beyond.

Curr Treat Options Oncol. 2023-11

[8]
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

Eur J Cancer. 2022-1

[9]
The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.

J Can Assoc Gastroenterol. 2019-2

[10]
The Role of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapies in Early-Stage Breast Cancer: Current Practices, Treatment De-escalation, and Future Prospects.

Cureus. 2024-2-29

引用本文的文献

[1]
Global research trends in tryptophan metabolism and cancer: a bibliometric and visualization analysis (2005-2024).

Front Oncol. 2025-7-1

[2]
Surfactant-Enabled Nanocarriers in Breast Cancer Therapy: Targeted Delivery and Multidrug Resistance Reversal.

Pharmaceutics. 2025-6-13

[3]
Assessment of Anticancer Effects of Aloe vera on 3D Liver Tumor Spheroids in a Microfluidic Platform.

Biotechnol Bioeng. 2025-9

[4]
Surface Modification, Toxicity, and Applications of Carbon Dots to Cancer Theranosis: A Review.

Nanomaterials (Basel). 2025-5-22

[5]
Targeting inflammation in cancer therapy: from mechanistic insights to emerging therapeutic approaches.

J Transl Med. 2025-5-26

[6]
Probing into the chemopreventive properties of synthetic 1,3,6-tri-O-galloyl-α-D-glucose (α-TGG) against glioblastoma and triple-negative breast cancer-derived cell models.

Curr Res Pharmacol Drug Discov. 2025-4-5

[7]
Addressing Challenges in Targeted Therapy for Metastatic Colorectal Cancer.

Cancers (Basel). 2025-3-25

[8]
Recent advances on anticancer activity of benzodiazine heterocycles through kinase inhibition.

RSC Adv. 2025-2-19

[9]
Recent Advances in Anticancer Strategies.

Cancers (Basel). 2025-1-8

[10]
Nasopharyngeal carcinoma with unusual metastatic spread to the spine and meninges: a case report with literature review.

J Surg Case Rep. 2025-1-23

本文引用的文献

[1]
Multitarget Mechanisms of Monocarbonyl Curcuminoid Analogues against HL-60 Cancer Cells: and Network Pharmacology-Based Approach.

ACS Omega. 2024-2-27

[2]
CAR T cells for hematological malignancies.

J Clin Invest. 2024-1-16

[3]
An Overview of Cancer in Djibouti: Current Status, Therapeutic Approaches, and Promising Endeavors in Local Essential Oil Treatment.

Pharmaceuticals (Basel). 2023-11-16

[4]
Next-Generation sequencing transforming clinical practice and precision medicine.

Clin Chim Acta. 2023-11-1

[5]
Treatment of evolving cancers will require dynamic decision support.

Ann Oncol. 2023-10

[6]
Advances in Molecular Medicine: Unravelling Disease Complexity and Pioneering Precision Healthcare.

Int J Mol Sci. 2023-9-16

[7]
Novel epigenetic molecular therapies for imprinting disorders.

Mol Psychiatry. 2023-8

[8]
Next-Generation Sequencing Technology: Current Trends and Advancements.

Biology (Basel). 2023-7-13

[9]
Enhancing head and neck tumor management with artificial intelligence: Integration and perspectives.

Semin Cancer Biol. 2023-10

[10]
Advances of medical nanorobots for future cancer treatments.

J Hematol Oncol. 2023-7-14

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索